|
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (FDA) for triamcinolone acetonide cream USP, 0.1%, the generic version of Kenalog cream, 0.1% of Delcor Asset Corporation (which is no longer being marketed in the United States).
According to IMS Health sales data for the 12 month period ending June 2016, the Kenalog cream, 0.1% market1 achieved annual sales of approximately $43.6 million.
Glenmark’s current portfolio consists of 108 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
|